Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.

Academic Article


  • BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown. OBJECTIVE: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART. METHODS: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50  copies/ml within 3-9 months after ART initiation. LLV50-199 was defined as two consecutive viral loads between 50 and 199  copies/ml and LLV200-499 as two consecutive viral loads between 50 and 499  copies/ml, with at least one between 200 and 499  copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500  copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death. RESULTS: Among 17 902 patients, 624 (3.5%) experienced LLV50-199 and 482 (2.7%) LLV200-499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200-499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05-5.17]. LLV50-199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96-2.00). LLV50-199 and LLV200-499 were not associated with AIDS event/death (aHR 1.13, 95% CI 0.81-1.68; and aHR 0.95, 95% CI 0.62-1.48, [corrected] respectively). CONCLUSION: LLV200-499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200  copies/ml.
  • Published In

  • AIDS  Journal
  • Keywords

  • Adult, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Europe, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, North America, Prognosis, Survival Analysis, Treatment Outcome, Viral Load, Viremia
  • Digital Object Identifier (doi)

    Author List

  • Antiretroviral Therapy Cohort Collaboration (ART-CC); Vandenhende M-A; Ingle S; May M; Chene G; Zangerle R; Van Sighem A; Gill MJ; Schwarze-Zander C; Hernandez-Novoa B
  • Start Page

  • 373
  • End Page

  • 383
  • Volume

  • 29
  • Issue

  • 3